Last reviewed · How we verify
Aspirin + Atorvastatin
This combination reduces cardiovascular risk by inhibiting platelet aggregation (aspirin) and lowering LDL cholesterol (atorvastatin).
This combination reduces cardiovascular risk by inhibiting platelet aggregation (aspirin) and lowering LDL cholesterol (atorvastatin). Used for Secondary prevention of cardiovascular events in patients with established coronary artery disease or high cardiovascular risk, Primary prevention of myocardial infarction and stroke in high-risk patients.
At a glance
| Generic name | Aspirin + Atorvastatin |
|---|---|
| Sponsor | Fundacion GESICA |
| Drug class | Antiplatelet agent + HMG-CoA reductase inhibitor (statin) |
| Target | Cyclooxygenase (COX) + HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Aspirin irreversibly inhibits cyclooxygenase (COX), preventing thromboxane A2 synthesis and platelet aggregation, thereby reducing thrombotic events. Atorvastatin is an HMG-CoA reductase inhibitor that lowers LDL cholesterol and reduces atherosclerotic plaque formation. Together, they provide complementary cardioprotective effects through antiplatelet and lipid-lowering mechanisms.
Approved indications
- Secondary prevention of cardiovascular events in patients with established coronary artery disease or high cardiovascular risk
- Primary prevention of myocardial infarction and stroke in high-risk patients
Common side effects
- Gastrointestinal bleeding
- Dyspepsia
- Muscle pain (myalgia)
- Elevated liver enzymes
- Headache
- Rash
Key clinical trials
- Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation (PHASE4)
- Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (PHASE4)
- Weak Pulse at Yang and Wiry Pulse at Yin Theory (NA)
- Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease (PHASE3)
- to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban (PHASE1)
- A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI) (PHASE3)
- Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Artery Stenosis Patients: A Cohort Study
- The Therapeutic Effect of Phase I Cardiac Rehabilitation on Elderly Patients With CHD Complicated by Sarcopenia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aspirin + Atorvastatin CI brief — competitive landscape report
- Aspirin + Atorvastatin updates RSS · CI watch RSS
- Fundacion GESICA portfolio CI